ClinicalTrials.gg
RecruitingNCT07687017CRP-SHOCKUpdated Oct 27, 2026

CRP Apheresis in Infarct-Related Cardiogenic Shock

An interventional study of Selective C-reactive protein apheresis (PentraSorb®-CRP) and Standard of care in Cardiogenic Shock and Acute Myocardial Infarction (AMI), sponsored by Leipzig Heart Science gGmbH. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Leipzig Heart Science gGmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 27, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.

Planned enrollment
12th of 22
50 · median 60
Started
2026
with 1 other
No phase
13 of 36
4 open now
Primary completion
2027-09
later than 5 of 12 live
Registered
34th of 36
by date
Lead sponsor
2 of 36
Leipzig Heart Science gGmbH

Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 34th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Shock, Cardiogenic with a site in Germany, or all of them as a file.
02

Study summary

Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction.

The CRP-SHOCK trial is an investigator-initiated, prospective, randomized, open-label, multicenter pilot study evaluating selective CRP apheresis as an adjunct to standard of care in patients with infarct-related cardiogenic shock. Patients are randomized to receive either standard therapy alone or standard therapy plus selective CRP apheresis using the PentraSorb®-CRP system.

The primary objective is to assess the effect of CRP apheresis on the CLIP score at 66 ± 8 hours after randomization. Secondary objectives include clinical outcomes, inflammatory biomarkers, and safety endpoints.

Read the detailed description

Cardiogenic shock following acute myocardial infarction is associated with a high inflammatory response and mortality rates of approximately 40-50% despite early revascularization and intensive care treatment. Experimental and clinical evidence suggests that elevated C-reactive protein (CRP) contributes to myocardial injury, impaired tissue regeneration, and adverse outcomes.

The CRP-SHOCK trial investigates whether selective removal of circulating CRP by apheresis improves short-term risk stratification and clinical outcomes in patients with infarct-related cardiogenic shock. The intervention consists of up to three CRP apheresis sessions initiated within 5 ± 1 hours after randomization and repeated at predefined intervals using the PentraSorb®-CRP system.

The primary efficacy endpoint is the CLIP score at 66 ± 8 hours after randomization. Secondary endpoints include mortality, major adverse cardiovascular events, biomarkers of inflammation and organ function, and safety outcomes such as bleeding, stroke, and infections. The trial is conducted as a multicenter pilot study in Germany and Austria.

03

Conditions studied

  • Cardiogenic Shock
  • Acute Myocardial Infarction (AMI)

Keywords

  • C-reactive protein
  • CRP apheresis
  • Selective CRP apheresis
  • Inflammation
  • Infarct-related cardiogenic shock
  • Acute myocardial infarction
  • CLIP score
  • PentraSorb-CRP
  • Pilot study
  • Multicenter study
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiogenic shock complicating acute myocardial infarction with planned revascularization by percutaneous coronary intervention (PCI).
  • Cardiogenic shock defined as:
  • Systolic blood pressure \<90 mmHg for >30 minutes or requirement of catecholamine infusion to maintain systolic blood pressure ≥90 mmHg, and
  • Signs of impaired organ perfusion (at least one of the following): Cold, clammy skin and extremities, Altered mental status, Oliguria with urine output \<30 mL/hour, Arterial lactate >2 mmol/L
  • C-reactive protein (CRP) level ≥7 mg/L at baseline.
  • Age ≥18 years.
  • provided by the participant or, if the participant is unable to consent, inclusion after assessment and documentation of the presumed patient's will by two physicians (one independent), with informed consent obtained as soon as possible.

Exclusion criteria

Exclusion Criteria:

  • Fever (body temperature >38°C) or acute infection with fever within the last 14 days.
  • Chronic inflammatory disease.
  • Known history of severe hepatic failure.
  • Chronic kidney disease with \<30 mL/min/1.73 m² prior to hospital admission.
  • \<12 months prior to cardiogenic shock.
  • Participation in another interventional clinical trial.
  • Pregnancy.
  • Resuscitation duration >30 minutes.
  • Cardiogenic shock due to causes other than acute myocardial infarction.
  • Onset of cardiogenic shock >12 hours before randomization.
  • Age >80 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Selective CRP Apheresis plus Standard of Care

    Participants receive standard of care for infarct-related cardiogenic shock plus selective C-reactive protein (CRP) apheresis using the PentraSorb®-CRP system. CRP apheresis is initiated within 5 ± 1 hours after randomization and repeated at 30 ± 4 hours and 54 ± 6 hours after randomization.

    Device: Selective C-reactive protein apheresis (PentraSorb®-CRP) · Other: Standard of care

  • Active comparator
    Standard of Care

    Participants receive guideline-directed standard of care for infarct-related cardiogenic shock without CRP apheresis.

    Other: Standard of care

Interventions

  • DeviceSelective C-reactive protein apheresis (PentraSorb®-CRP)

    Selective removal of circulating C-reactive protein using the PentraSorb®-CRP adsorber system as an adjunct to guideline-directed standard of care.

    Also known as: CRP Apheresis plus Standard of Care

  • OtherStandard of care

    Guideline-directed medical and interventional treatment for cardiogenic shock complicating acute myocardial infarction.

06

What researchers measure

Primary outcomes

  1. CLIP score

    The CLIP score (Cystatin C, Lactate, Interleukin-6 and N-terminal pro B-type natriuretic peptide \[NT-proBNP\] score) is a biomarker-based risk score for predicting 30-day mortality in cardiogenic shock complicating acute myocardial infarction. It is calculated via a logistic regression model using the four biomarkers (Cystatin C, Lactate, Interleukin-6, and NT-proBNP), yielding a probability score ranging from 0 to 1 (or 0% to 100% when multiplied by 100). Higher scores indicate a higher probability of 30-day mortality, i.e., a worse outcome.

    Time frame: 66 ± 8 hours after randomization

Secondary outcomes

  1. Major adverse cardiovascular events (MACE)

    Composite endpoint of cardiovascular death, non-fatal myocardial infarction, or re-admission for heart failure.

    Time frame: 30 days

  2. All-cause mortality

    Death from any cause within 30 days after randomization.

    Time frame: 30 days

  3. Cardiovascular mortality

    Death due to cardiovascular causes within 30 days after randomization.

    Time frame: 30 days

  4. CLIP score over time

    The CLIP score (Cystatin C, Lactate, Interleukin-6 and N-terminal pro B-type natriuretic peptide \[NT-proBNP\] score) is a biomarker-based risk score for predicting 30-day mortality in cardiogenic shock complicating acute myocardial infarction. It is calculated via a logistic regression model using the four biomarkers (Cystatin C, Lactate, Interleukin-6, and NT-proBNP), yielding a probability score ranging from 0 to 1 (or 0% to 100% when multiplied by 100). Higher scores indicate a higher probability of 30-day mortality, i.e., a worse outcome.

    Time frame: 18 ± 4 hours, 42 ± 6 hours, and 66 ± 8 hours after randomization

  5. Individual components of the CLIP score

    The CLIP score (Cystatin C, Lactate, Interleukin-6 and N-terminal pro B-type natriuretic peptide \[NT-proBNP\] score) is a biomarker-based risk score for predicting 30-day mortality in cardiogenic shock complicating acute myocardial infarction. It is calculated via a logistic regression model using the four biomarkers (Cystatin C, Lactate, Interleukin-6, and NT-proBNP), yielding a probability score ranging from 0 to 1 (or 0% to 100% when multiplied by 100). Higher scores indicate a higher probability of 30-day mortality, i.e., a worse outcome.

    Time frame: 18 ± 4 hours, 42 ± 6 hours, and 66 ± 8 hours after randomization

  6. C-reactive protein (CRP) concentration

    Serum CRP concentrations measured before and after CRP apheresis sessions.

    Time frame: 9 ± 1 hours, 34 ± 4 hours, 58 ± 6 hours, and 66 ± 8 hours after randomization

  7. Peak NT-proBNP concentration

    Maximum NT-proBNP serum concentration recorded during the index hospital stay.

    Time frame: During index hospitalization

  8. Peak serum creatinine concentration

    Maximum serum creatinine concentration recorded during the index hospital stay.

    Time frame: During index hospitalization

  9. Cardiac power index

    The Cardiac Power Index (CPI) is a continuous hemodynamic measurement reflecting the rate of cardiac energy output indexed to body surface area, calculated as cardiac index × mean arterial pressure × a constant (W/m²). It is not a score on a defined scale but a continuous physiological parameter without fixed minimum or maximum values. Normal values are generally reported in the range of 0.5-0.7 W/m². Lower CPI values are associated with worse outcomes, including higher mortality, need for cardiac transplantation, or ventricular assist device placement - thus, higher values indicate better cardiac performance.

    Time frame: 18 ± 4 hours, 42 ± 6 hours, and 66 ± 8 hours after randomization

  10. Time to hemodynamic stabilization

    Time from randomization to sustained hemodynamic stabilization as defined by the treating physician.

    Time frame: hospital discharge

  11. Duration of catecholamine therapy

    Total duration of vasopressor and inotropic support.

    Time frame: hospital discharge

  12. Length of intensive care unit stay

    Number of days spent in the intensive care unit.

    Time frame: hospital discharge

  13. Length of hospital stay

    Total length of hospital stay in days.

    Time frame: hospital discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pöss J, Köster J, Fuernau G, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. European Heart Journal. 2017;38:386-396.
  • Slagman A, Searle J, Müller C, et al. C-reactive protein apheresis in acute myocardial infarction: results of the CAMI-1 study. Clinical Research in Cardiology. 2021;110:1597-1606.
  • Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012 Oct 4;367(14):1287-96. doi: 10.1056/NEJMoa1208410. Epub 2012 Aug 26. PubMed 22920912 ↗
  • Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U; CULPRIT-SHOCK Investigators. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017 Dec 21;377(25):2419-2432. doi: 10.1056/NEJMoa1710261. Epub 2017 Oct 30. PubMed 29083953 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly. Access to de-identified data may be considered upon reasonable request and subject to approval by the study sponsor and applicable ethics committees.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Jul 7, 2026
StartActual
Oct 16, 2026was Jul 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Oct 31, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
Heart Center Leipzig at University of Leipzig is now Recruiting
Oct 27, 2026
Start date
Jul 20, 2026→Oct 16, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    Heart Center Leipzig at University of Leipzig is now Recruiting
    Start date Jul 20, 2026→Oct 16, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07687017
Lead sponsor
Leipzig Heart Science gGmbH
Collaborators
Helios Health Institute GmbH, Heart Center Leipzig at University of Leipzig
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Oct 16, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

CRP-SHOCK Leipzig Heart Science gGmbH
Contact
CRP-SHOCK@leipzig-heart.de
+49 341 865 251556
Prof. Dr. med. Holger Thiele Thiele
principal investigator · Heart Center Leipzig at University of Leipzig

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion